Introduction: Effective management of type 2
INTRODUCTION
Worldwide, an estimated 366 million people had diabetes in 2011 and the number is expected to grow to 552 million by 2030 [1] . The 2005-2006 National Health and Nutrition Examination Survey of community-dwelling adults showed that the prevalence of diabetes increases with age, peaking at 60-74 years of age (crude prevalence 17.6%) [2] .
Effective management of diabetes requires sustained glycemic control over many years.
This can be a challenge for all patients with diabetes, but particularly in elderly people with type 2 diabetes, due to co-morbidities and polypharmacy, among other issues.
Furthermore, elderly patients may find it difficult to adequately self-monitor blood sugar levels due to poor dexterity, and cognitive and visual impairments, and may have impaired awareness of hypoglycemia compared with younger patients [3, 4] .
Consequently, elderly people with type 2 diabetes have a higher rate of severe hypoglycemia than younger people with type 2 diabetes [5, 6] .
Insulin analogs were developed to help people with diabetes improve their glycemic control and to address concerns over insulin therapy, particularly hypoglycemia and weight gain [7, 8] . Randomized controlled trials (RCTs) and non-interventional studies [9] [10] [11] [12] [13] [14] [15] [16] have shown that a change of therapy from oral glucose-lowering drugs (OGLDs) or conventional insulin preparations to insulin analogs can be associated with clinically significant improvements in effectiveness measures and tolerability.
For many patients, biphasic insulin formulations offer a simple-to-use insulin regimen [17] , providing greater lifestyle flexibility for the patient; they also offer the advantage of controlling both fasting plasma glucose (FPG) and post-prandial glucose (PPG) [18, 19] . Biphasic insulin aspart 30 (NovoMix Ò 30; Novo Nordisk A/S, Bagsvaerd, Denmark) may lead to improved PPG control compared with other insulin therapies, including premixed biosynthetic human insulin 30, and biphasic insulin lispro [20] . Furthermore, initiating insulin therapy with once-or twice-daily biphasic insulin aspart 30 (in people with type 2 diabetes on various OGLD regimens) effectively controls glycated hemoglobin (HbA 1c ) levels [18, 19] . Indeed, one study showed that significantly more insulin-naïve people with type 2 diabetes randomized to twice-daily biphasic insulin aspart 30 achieved HbA 1c \7.0% than those randomized to once-daily insulin glargine, especially among people with baseline HbA 1c [8. 5% [19] . Non-inferiority of once-daily biphasic insulin aspart 30 to once-daily insulin glargine has also been shown in people with type 2 diabetes inadequately controlled with OGLDs [21] . The effectiveness of biphasic insulin aspart 30 seen in short-term studies is maintained with long-term use [22, 23] [24] .
Insulin analogs were used in the study in accordance with the label approved by the regulatory authority (all manufactured by Novo Nordisk A/S, Bagsvaerd, Denmark), and all local requirements for Health Authorities or Ethics Committee approvals were obtained, if applicable. In every country, participants signed informed consent forms and were free to withdraw from the study at any time. The study was conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2008 [25] and guidelines for good pharmacoepidemiology practice [26] .
Assessments and Outcome Measures
Trial visits were defined as baseline, interim [around 12 weeks from baseline (results not reported here)], and final visit (around 24 weeks from baseline). The amount of starting insulin and the amount of insulin administered at subsequent visits were recorded.
The primary objective was to evaluate the safety profile of insulin analogs by measuring the incidence of serious adverse drug reactions (SADRs), including major hypoglycemia events.
Other safety assessments included the change in the number of hypoglycemia events (overall, HRQoL was assessed at baseline and after 24 weeks by self-reporting using the EQ-5D questionnaire [27] , which evaluates five domains of patient health/lifestyle (mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression). Patient responses were evaluated on a visual analog scale (VAS) of 0 (worst imaginable health) to 100 (best imaginable health).
Statistical Analysis
This publication reports the results for patients who were administered biphasic insulin aspart 30 (±OGLDs) to be related to study insulin was also reported. Change from baseline data in effectiveness measures were analyzed using paired t test. All data were analyzed by Novo Nordisk A/S using SAS Ò Version 9.1.3 (SAS Ò Institute Inc., Cary, NC, USA). The statistical significance level employed was a = 0.05 (two tailed). Missing data were not imputed. The sample size was based on the number of people (20,000) exposed for 6 months required to confirm at 95% confidence a frequency of any one adverse drug reaction of C15 events/100,000 personyears.
RESULTS

Study Participants
Of the total A 1 chieve study population, 40,122 people with type 2 diabetes received treatment with biphasic insulin aspart 30 (±OGLDs). This included 4,347 people aged B40 years, 29,036
people aged [40-65 years, and 6,739 people aged [65 years (Table 1) . Due to the noninterventional nature of the study, some baseline data were missing and some patients were missing to follow-up. Most study participants (67%) were insulin-naïve before the study. The [65 years age-group had the longest diabetes duration (Table 1 ).
Exposure
The difference between the starting insulin dose and the insulin dose at 24 weeks in any agegroup was small. In the B40 years age-group, the starting mean (SD) total insulin dose was 0.46 (Table 2) ; although the [65 years age-group tended to be receiving less OGLDs at 24 weeks than the B40 and [40-65 years age-groups, there was no major difference in OGLD use between the age-groups (Table 2 ). Metformin and/or sulfonylureas were the predominant OGLDs in all age-groups at study initiation and after 24 weeks of treatment with biphasic Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up BMI body mass index a n = 4,342, n = 29,008 and n = 6,739 for the B40 years, [40-65 years and [65 years age-groups, respectively b n = 4,161, n = 27,744, and n = 6,361 for the B40 years, [40-65 years and [65 years age-groups, respectively c n = 3,916, n = 25,885, and n = 5,892 for the B40 years, [40-65 years and [65 years age-groups, respectively d n = 4,109, n = 28,815 and n = 6,673 for the B40 years, [40-65 years and [65 years age-groups, respectively insulin aspart 30; [70% of patients in all agegroups were prescribed metformin after 24 weeks.
Safety Measures
All Hypoglycemia Events
After 24 weeks, the proportion of participants experiencing hypoglycemia events in the entire cohort decreased significantly from baseline in all age-groups (all p\0.01; Table 3 ). This pattern was also seen among insulin-experienced participants (all p\0.001; Table 3 ). As with the insulin-experienced group, there was a significant reduction in the proportion of insulin-naïve participants experiencing hypoglycemia in the B40 years age-group (p\0.05); however, there was no statistically significant change in the [40-65 years age-group and a significant increase in the [65 years age-group (p\0.001; Table 3 ). There did not appear to be a trend between the length of time in years from diagnosis of diabetes and total hypoglycemia events (results not shown). Neither did there seem to be an association between sulfonylurea use and the total number of hypoglycemia events (Table 3) .
Major Hypoglycemia Events
The proportions of participants experiencing major hypoglycemia in the entire cohort and in insulin-experienced patients decreased significantly from baseline in all age-groups following 24 weeks' therapy with biphasic insulin aspart 30 (all p\0.001; Table 3 ). In insulin-naïve patients, there were significant reductions from baseline in the proportion of participants experiencing major hypoglycemia in the [40-65 years and [65 years age-groups (both p\0.001; Table 3 ), but no significant difference from baseline in the B40 years agegroup.
Nocturnal Hypoglycemia Events
The proportions of participants experiencing nocturnal hypoglycemia in the entire cohort and in insulin-experienced patients decreased significantly from baseline in all age-groups following 24 weeks' therapy with biphasic insulin aspart 30 (all p\0.001; Table 3 ). The proportion of insulin-naïve patients experiencing nocturnal hypoglycemia was significantly reduced in the B40 and [40-65 years age-groups at 24 weeks (both p\0.001), with no significant change reported in the[65 years age-group (Table 3) . Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up OGLDs oral glucose-lowering drugs 
Body Weight
There was a modest, but statistically significant (p\0.001), weight gain (0.2-0.7 kg) after 24 weeks in all age-groups (Table 3) . Weight gain with biphasic insulin aspart 30 treatment appeared to be similar in both insulin-experienced and insulinnaïve patients (Table 3) .
Effectiveness Measures
Glycemic Measures
Mean baseline HbA 1c levels were high in all agegroups (ranging from 9.4% to 9.6%), and after 24 weeks of treatment with biphasic insulin aspart 30, all age-groups showed statistically significant improvements (p\0.001; Table 4 ).
Likewise, HbA 1c levels were statistically significantly reduced in all age-groups after 24 weeks in insulin-experienced and insulinnaïve patients (p\0.001; Table 4 ). In all agegroups, improvements in HbA 1c values appeared to be greater in insulin-naïve patients than in insulin-experienced patients (Table 4 ). The length of time since diagnosis of diabetes in years did not appear to affect the magnitude of reduction in HbA 1c levels after 24 weeks of biphasic insulin aspart 30 treatment (results not shown).
Mean baseline FPG was high in all agegroups (ranging from 10.5 to 11.1 mmol/l), and there were significant improvements in all age-groups after 24 weeks' treatment with biphasic insulin aspart 30 (Table 4) .
Improvements in FPG appeared to be slightly greater in the insulin-naïve group than the insulin-experienced group after 24 weeks in all age-groups (Table 4) . Likewise, baseline PPG was high in all age-groups, and after 24 weeks' treatment with biphasic insulin aspart 30, statistically significantly improvements were observed in all age-groups (Table 4) .
Improvements after 24 weeks appeared to be greater in the insulin-naïve group in all agegroups (Table 4) . Improvements in FPG and PPG levels at 24 weeks appeared to be greatest in the Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up *** p\0.001 vs. baseline ** p\0.01 vs. baseline * p\0.05 vs. baseline Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up FPG fasting plasma glucose, 
HRQoL
There was statistically significant (p\0.001) improvement in VAS scores after 24 weeks in all age-groups (Table 4) . Statistically significant increases in VAS scores were observed for both insulin-experienced and insulin-naïve patients in all age-groups (p\0.001; Table 4 ).
DISCUSSION
This sub-analysis of age-specific data from the A 1 chieve study showed that starting, or switching to, insulin therapy with biphasic insulin aspart 30 (±OGLDs) under routine clinical practice led to significant improvements in blood glucose levels (as measured by HbA 1c , FPG and PPG) across 3 age-groups. These results are consistent with previous studies that showed in people with type 2 diabetes that starting insulin therapy with once-or twice-daily biphasic insulin aspart 30 led to effective glycemic control [18, 19] . Another study also showed that biphasic insulin aspart 30 may lead to improved PPG control compared with other insulin therapies [20] .
Importantly, the significant improvement in glycemic control was achieved with a significant reduction in the proportion of participants in the entire cohort reporting major hypoglycemia during the 24 weeks of treatment with biphasic insulin aspart 30
(±OGLDs) relative to baseline. The results appeared to be generally consistent across the 3 age-groups assessed and between insulinnaïve and insulin-experienced patients. Some variation in the specific pattern of results was observed and these will be discussed. [28] . Furthermore, the proportion of participants reporting hypoglycemia was significantly reduced in all age-groups switching from other insulin regimens to biphasic insulin aspart 30 treatment, as would be expected from the significant reductions in the whole A 1 chieve study population [24] . This result may also have been driven by the high baseline values in all age-groups of insulin-experienced participants. However, while the proportion was also significantly reduced in insulin-naïve patients aged B40 years, it was significantly increased in the [65 years age-group. Elderly individuals with diabetes are at higher risk of hypoglycemia than younger people due to risk factors such as co-morbidities, polypharmacy, and cognitive impairment [29] -this may explain the age differences in hypoglycemia rates. Reported major hypoglycemia episodes were rare during treatment with biphasic insulin aspart 30, as seen in other noninterventional studies [30] , with statistically significant improvements from baseline in all age-groups. Furthermore, there was a low incidence of SADRs in all three age-groups, with no suggestion that these were more likely in one group over another. While it is not surprising that patients already receiving insulin therapy at baseline had what appeared to be higher rates of overall hypoglycemia, major hypoglycemia and nocturnal hypoglycemia than those who were insulinnaïve pre-study, it is unclear why the Diabetes Ther (2013) 4:347-361 357
proportion of patients reporting nocturnal hypoglycemia at baseline appeared to be much higher among insulin-experienced patients in the B40 years age-group.
Changes to body weight with biphasic insulin aspart 30 therapy were modest (generally \1 kg); weight gain was greatest in the [65 years age-group, but the differences between age-groups were not large and may not have any clinical relevance. As expected, insulin-experienced patients appeared to weigh more at baseline than insulin-naïve participants in all age-groups, but there was no clear difference in weight gain between the 2 groups after 24 weeks in any age-group. Other studies have reported weight gain with use of biphasic insulin aspart 30 [12, 19, 31] [26] .
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